康恩贝子公司TFA003片获得药物临床试验批准通知书

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are intended for the treatment of diabetic kidney disease [1] Company Summary - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has been granted the Clinical Trial Approval Notice for TFA003 tablets [1] - The approval indicates that TFA003 tablets meet the registration requirements for pharmaceuticals as per the relevant regulations [1] - The clinical trial is set to proceed after further refinement of the clinical trial protocol [1]